Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for MNTA
15.95
-0.10 (-0.62%)
After Hours: 16.05 +0.10 (0.63%)
Feb 20, 5:00PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.60 - 16.35
52 week 11.85 - 19.25
Open 15.90
Vol / Avg. 841,947.00/935,212.00
Mkt cap 1.22B
P/E     -
Div/yield     -
EPS -0.80
Shares 76.39M
Beta 1.80
Inst. own 102%
Feb 21, 2018
Q4 2017 Momenta Pharmaceuticals Inc Earnings Call - 10:00AM EST - Add to calendar
Feb 21, 2018
Q4 2017 Momenta Pharmaceuticals Inc Earnings Release - 9:30AM EST - Add to calendar
Feb 15, 2018
Momenta Pharmaceuticals Inc at Leerink Partners Global Healthcare Conference
Jan 8, 2018
Momenta Pharmaceuticals Inc at JPMorgan Healthcare Conference - Questions & Answers Session
Jan 8, 2018
Momenta Pharmaceuticals Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -137.77% -19.16%
Operating margin -143.32% -68.17%
EBITD margin - -59.84%
Return on average assets -25.52% -4.67%
Return on average equity -35.62% -5.66%
Employees 290 -
CDP Score - -

Address

675 W Kendall St
CAMBRIDGE, MA 02142-1110
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Officers and directors

Craig A. Wheeler President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Scott M. Storer Chief Financial Officer, Senior Vice President
Age: 42
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Chief Operating Officer, Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Bruce A. Leicher Senior Vice President, General Counsel, Secretary
Age: 60
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 69
Bio & Compensation  - Reuters
Corey N. Fishman Independent Director
Age: 52
Bio & Compensation  - Reuters
Georges Gemayel Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Steven C. Gilman Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Jose-Carlos Gutierrez-Ramos Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters